TY - JOUR
T1 - Sex-Specific Differences in Patients With Psoriatic Arthritis
T2 - A Systematic Review
AU - Coates, Laura C.
AU - van der Horst-Bruinsma, Irene E.
AU - Lubrano, Ennio
AU - Beaver, Steph
AU - Drane, Emma
AU - Ufuktepe, Baran
AU - Ogdie, Alexis R.
N1 - Funding Information:
This study was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Costello Medical, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). The authors acknowledge Susana Lobo Berastegui, MSc, MBA, UCB Pharma, Madrid, Spain, for publication coordination. The authors also acknowledge Harry Freeman, BSc, Emma Worthington, MPH, and Ashley Jaggi, PhD, from Costello Medical for support with the SLR, as well as Ashley Jaggi, PhD, and Lucy Berry, MBBS, from Costello Medical for medical writing and editorial assistance based on the authors' input and direction.
Funding Information:
This study was sponsored by UCB Pharma. Support for third-party writing assistance for this article, provided by Costello Medical, was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3). 1L.C. Coates, MBChB, MRCP, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, Oxfordshire, UK; 2I.E. van der Horst-Bruinsma, MD, PhD, Department of Rheumatology, ZH0D53, Amsterdam UMC/VU University Medical Centre, Amsterdam, the Netherlands; 3E. Lubrano, MD, MSc, PhD, Dipartimento di Medicina e Scienze, Della Salute “Vincenzo Tiberio,” Università degli Studi del Molise, Campobasso, Italy; 4S. Beaver, MSc, E. Drane, PhD, Costello Medical Consulting Ltd, Cambridge, Cambridgeshire, UK; 5B. Ufuktepe, MD, PhD, UCB Pharma A.S. (Turkey), Istanbul, Turkey; 6A.R. Ogdie, MD, MSCE, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. LCC received grant/research support from AbbVie, Amgen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma; received consulting fees from AbbVie, Amgen, Biogen, BI, Celgene, Domain, Gilead, Janssen, and Lilly; and is on the speaker’s bureau for AbbVie, Amgen, Biogen, Celgene, Gilead, GSK, Janssen, Lilly, medac, Novartis, Pfizer, and UCB Pharma. IEvdHB received grant/research support from AbbVie, MSD, and Pfizer; is a consultant for AbbVie, MSD, Novartis, and UCB Pharma; and is on the speaker’s bureau for AbbVie, BMS, MSD, and Pfizer. EL is a consultant for AbbVie, Celgene, Novartis, Pfizer, and UCB Pharma. SB and ED are employees of Costello Medical. BU is an employee of UCB Pharma. ARO received grant/research support for the researcher’s institution from Pfizer and Novartis to the University of Pennsylvania and from Amgen to Forward/NDB and is a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Janssen, Novartis, and Pfizer. Address correspondence to Dr. L.C. Coates, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford, OX3 7HE, UK. Email: laura.coates@ndorms.ox.ac.uk. Accepted for publication September 28, 2022.
Publisher Copyright:
© 2023 The Journal of Rheumatology. This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - OBJECTIVE: A systematic review of published literature was conducted to collate evidence on sex-specific differences in clinical characteristics, disease activity, and patient-reported outcomes (PROs) in psoriatic arthritis (PsA), including response to treatment. METHODS: Searches of MEDLINE, Embase, and the Cochrane Database of Systematic Reviews were performed in November 2020 for observational studies of adults with PsA reporting outcomes by sex (published from January 1, 2015, to November 13, 2020). In addition, hand searches of systematic literature reviews and (network) metaanalysis bibliographies were performed. Searches of ClinicalTrials.gov and congress abstracts from the European Alliance of Associations for Rheumatology, the American College of Rheumatology (ACR), and the American Academy of Dermatology (2019-2020) were also carried out. Eligible studies with 100 or more patients prespecified a comparison by sex and reported clinical characteristics and/or disease activity. Data extracted included patient characteristics, study design, baseline clinical characteristics, and disease activity results, including PROs. RESULTS: Database searching yielded 3283 unique records; 31 publications of 27 unique studies were included. The review found generally higher rates of peripheral disease in women, including higher tender joint counts. There was some evidence of more axial disease in men, plus greater skin disease burden. There were consistently no differences in Dermatology Life Quality Index scores, though across other PROs, women had worse scores, including pain and fatigue. Women had poorer responses to treatment, indicated by outcome measures such as ACR responses and minimal disease activity. CONCLUSION: This review indicates that important differences exist between the sexes in PsA. However, the limited evidence for this conclusion underlines the need for additional research in this area.
AB - OBJECTIVE: A systematic review of published literature was conducted to collate evidence on sex-specific differences in clinical characteristics, disease activity, and patient-reported outcomes (PROs) in psoriatic arthritis (PsA), including response to treatment. METHODS: Searches of MEDLINE, Embase, and the Cochrane Database of Systematic Reviews were performed in November 2020 for observational studies of adults with PsA reporting outcomes by sex (published from January 1, 2015, to November 13, 2020). In addition, hand searches of systematic literature reviews and (network) metaanalysis bibliographies were performed. Searches of ClinicalTrials.gov and congress abstracts from the European Alliance of Associations for Rheumatology, the American College of Rheumatology (ACR), and the American Academy of Dermatology (2019-2020) were also carried out. Eligible studies with 100 or more patients prespecified a comparison by sex and reported clinical characteristics and/or disease activity. Data extracted included patient characteristics, study design, baseline clinical characteristics, and disease activity results, including PROs. RESULTS: Database searching yielded 3283 unique records; 31 publications of 27 unique studies were included. The review found generally higher rates of peripheral disease in women, including higher tender joint counts. There was some evidence of more axial disease in men, plus greater skin disease burden. There were consistently no differences in Dermatology Life Quality Index scores, though across other PROs, women had worse scores, including pain and fatigue. Women had poorer responses to treatment, indicated by outcome measures such as ACR responses and minimal disease activity. CONCLUSION: This review indicates that important differences exist between the sexes in PsA. However, the limited evidence for this conclusion underlines the need for additional research in this area.
KW - gender
KW - patient-reported outcome measures
KW - psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85148217401&partnerID=8YFLogxK
U2 - 10.3899/jrheum.220386
DO - 10.3899/jrheum.220386
M3 - Article
C2 - 36243418
SN - 0315-162X
VL - 50
SP - 488
EP - 496
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 4
ER -